| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 10/21/2004 | WO2003000014A3 Spherical protein particles and methods of making and using them |
| 10/21/2004 | US20040210950 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS) |
| 10/21/2004 | US20040210042 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 10/21/2004 | US20040209942 treating cancer and apoptosis-associated disorders using cell cycle checkpoint activation modulators; also screening for the modulators |
| 10/21/2004 | US20040209840 Manipulation of arterial-venous identity |
| 10/21/2004 | US20040209839 Human peroxisome proliferator activated receptor gamma |
| 10/21/2004 | US20040209836 activation of antigen-presenting cells; modifying dendritic cells to express an inducible form of a co-stimulatory polypeptide molecule; used to bolster the immune response of an immunocompromised subject, such as an HIV-infected subject |
| 10/21/2004 | US20040209835 Process for preparing purified nucleic acid and the use thereof |
| 10/21/2004 | US20040209832 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 10/21/2004 | US20040209829 Oral treatment of hemophilia |
| 10/21/2004 | US20040209816 Treatment for diabetes |
| 10/21/2004 | US20040209805 such as fibrosis via activin antagonist (fullistatin); kits; gene therapy; treating inflammatory bowel disease and crohn's disease |
| 10/21/2004 | US20040209800 Use of mx gtpases in the prognosis and treatment of cancer |
| 10/21/2004 | US20040209369 Controlling gene expression in living cells |
| 10/21/2004 | US20040209366 Methods for attaching proteins to lipidic microparticles with high efficiency |
| 10/21/2004 | US20040209364 Enhancced adeno-associated viral vector for use as gene transfer tool in genetic engineering and gene therapy; antitumor agents |
| 10/21/2004 | US20040209342 Comprises nucleotide sequences coding hydrolase for use in identifying modulators for treatment of diabetes and inflammatory diseases |
| 10/21/2004 | US20040209326 Immunoglobulin for use in detection and prevention staphylococcus infections |
| 10/21/2004 | US20040209306 Novel proteins in enteroaggregative escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| 10/21/2004 | US20040209271 Dna providing system |
| 10/21/2004 | US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders |
| 10/21/2004 | US20040209247 Viral vector comprising E1 region for use as gene transfer tool in genetic engineering |
| 10/21/2004 | US20040209240 Anti-neoplastic viruses |
| 10/21/2004 | US20040208905 Gene delivery of a viral vector |
| 10/21/2004 | US20040208900 mutant rabies virus comprising a rabies virus N protein that is not phosphorylated; central nervous system (CNS) |
| 10/21/2004 | US20040208889 Pharmaceutical use for secreted bacterial effector proteins |
| 10/21/2004 | US20040208888 Method of and compositions for immunization with the pseudomonas v antigen |
| 10/21/2004 | US20040208886 DNA sequences encoding the proteins; drugs with the proteins or the DNA; for the preparation of antigens for treating tumoral diseases; administering |
| 10/21/2004 | US20040208878 Treatment of acute lung injury, fibrosis and metastasis with antagonists of alphabetav6 |
| 10/21/2004 | US20040208857 Producing a donor-specific immunotolerance against transplanted tissue by administering embryonic stem cell-like cell lines (ECL) obtained from blastocysts and are transfected with genetic material of the donor, which codes for the major histocompatibility complex (MHC) haplotypes |
| 10/21/2004 | US20040208851 Immunization by inoculation of DNA transcription unit |
| 10/21/2004 | US20040208850 Antitumor agents; enhanced by administration of cytoxic T lymphocyte (CTLA-4) blocker and/or cytosine-guanosine (CpG) oligodeoxynucleotide immunomodulators |
| 10/21/2004 | US20040208849 Reducing viability of tumor cell by administering virus that is not a common human pathogen such as a Rhabdovirus, a picomavirus, and preferably is vesicular stomatitis virus (VSV) |
| 10/21/2004 | US20040208848 Contains multiplicity of expressible coding sequences derived from the neoplastic cell, pathogen or parasite, and gene expression of coding sequences in a human or animal; immunogens for vaccines; antitumor and anticarcinogenic agents; viral replicon selected nucleic acid expression libraries |
| 10/21/2004 | US20040208847 Administering to mammal a vector particle exhibiting an adeno-associated virus-4 (AAV-4) capsid protein; vision defects |
| 10/21/2004 | US20040208846 Mini-Ad vector for immunization |
| 10/21/2004 | US20040205910 supplying hair dyes, melanin, proteins, nucleic acids; encapsulated in liposomes |
| 10/21/2004 | CA2809195A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| 10/21/2004 | CA2784829A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| 10/21/2004 | CA2548580A1 Elective collection and banking of autologous peripheral blood stem cells |
| 10/21/2004 | CA2528001A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 10/21/2004 | CA2521402A1 Pectate lyases, nucleic acids encoding them and methods for making and using them |
| 10/21/2004 | CA2521217A1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| 10/21/2004 | CA2520987A1 Targets for tumor growth inhibition |
| 10/21/2004 | CA2520775A1 Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| 10/21/2004 | CA2520028A1 Compounds and methods to enhance raav transduction |
| 10/21/2004 | CA2520016A1 Pharmico-gene therapy of epithelial sodium channel associated disorders |
| 10/21/2004 | CA2488224A1 Irna conjugates |
| 10/20/2004 | EP1469316A1 Screening method |
| 10/20/2004 | EP1469084A2 Polymorphisms in the human KDR gene |
| 10/20/2004 | EP1469077A1 Cell-specific expression/replication vector |
| 10/20/2004 | EP1469075A1 Gene-therapy for solid tumors, papillomas and warts |
| 10/20/2004 | EP1469073A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 10/20/2004 | EP1469009A2 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 10/20/2004 | EP1468698A2 Human quinone reductase 2 conjugates for adept and gdept |
| 10/20/2004 | EP1468118A2 Methods and compositions for treating cancer |
| 10/20/2004 | EP1468110A2 Molecular signatures of commonly fatal carcinomas |
| 10/20/2004 | EP1468097A2 METHODS OF GENERATING MULTISPECIFIC, MULTIVALENT AGENTS FROM V sb H /sb AND V sb L /sb DOMAINS |
| 10/20/2004 | EP1468094A1 Method of transducing es cells |
| 10/20/2004 | EP1468091A2 Transmembrane protein |
| 10/20/2004 | EP1468020A2 Multimers of receptor-binding ligands |
| 10/20/2004 | EP1468019A2 Secreted protein |
| 10/20/2004 | EP1468018A2 Leptin proteins |
| 10/20/2004 | EP1468014A2 Compositions and methods for wt1 specific immunotherapy |
| 10/20/2004 | EP1468011A1 Biomolecule transduction motif sim-2-btm and the use thereof |
| 10/20/2004 | EP1467752A1 HUMAN MAST CELL−EXPRESSED MEMBRANE PROTEINS |
| 10/20/2004 | EP1467711A2 Dna dosage forms |
| 10/20/2004 | EP1467624A2 Methods of inducing or enhancing connective tissue repair |
| 10/20/2004 | EP1181381B1 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 10/20/2004 | EP0821733B1 Genetic markers for breast and ovarian cancer |
| 10/20/2004 | CN1539012A Electrodes coated with treating agent and uses thereof |
| 10/20/2004 | CN1538849A Use of long PENTRAXIN PTX 3 for treating female infertility |
| 10/20/2004 | CN1537637A Nucleic acid vaccine |
| 10/20/2004 | CN1171997C Modified TLE-2-receptor ligands |
| 10/20/2004 | CN1171996C American pig reproduction and respiratory syndrome syndrome (PRRS) virus and its use |
| 10/20/2004 | CN1171640C Preparation method of liver cancer superantigen immunogene therapy agent |
| 10/19/2004 | US6806084 Comprises dna/lipid carrier complexes for transfection; for modulating the genotype and phenotype into two or more tissues following systemic administration; for gene therapy |
| 10/19/2004 | US6806080 Expression vector for use in human diagnositics and therapeutics |
| 10/19/2004 | US6806064 A viral nucleic acid construct for the high level expression of a heterologous protein in an insect cell; using baculovirus expression vector system for exogenous proteins production |
| 10/19/2004 | US6805863 Comprises antibodies/proteins providing inhibition of prothrombinase; treatment and prevention of bacterial and viral infections, allograft/xenograft rejection, glomerulo-nephritis, cancer, gastrointestinal diseases, and fetal loss |
| 10/19/2004 | US6805858 Methods for the administration of adenovirus p53 |
| 10/14/2004 | WO2004087931A1 Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
| 10/14/2004 | WO2004087930A1 Adenovirus replication-competent vectors expressing trail |
| 10/14/2004 | WO2004087926A1 A promoter construct for gene expression in neuronal cells |
| 10/14/2004 | WO2004087921A1 Human solid cancer antigen peptides, polynucleotides encoding the same and utilization thererof |
| 10/14/2004 | WO2004087920A1 Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof |
| 10/14/2004 | WO2004087873A2 Methods of treating xerostomia and xerophthalmia |
| 10/14/2004 | WO2004087862A2 Tak1-mediated inhibition of osteogenesis |
| 10/14/2004 | WO2004087752A2 Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders |
| 10/14/2004 | WO2004087751A1 Dystrophin-related protein (drop1), a marker for carcinomas |
| 10/14/2004 | WO2004087748A1 Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same |
| 10/14/2004 | WO2004087055A2 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| 10/14/2004 | WO2004072253A9 Human excitatory amino acid transporter-2 gene promoter and uses thereof |
| 10/14/2004 | WO2004060269A3 Mda-7 and free radicals in the treatment of cancer |
| 10/14/2004 | WO2004047623A3 Methods for identifying risk of breast cancer and treatments thereof |
| 10/14/2004 | WO2004044229A3 DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A2 (PDE7a2) |
| 10/14/2004 | WO2004024190A3 Recombinant lentivirale vector pseudotyped with the hemagglutinin protein for gene transfer into the retina |
| 10/14/2004 | WO2004021010A3 Method of diagnosing colon and gastric cancers |
| 10/14/2004 | WO2004004798A3 Central airway administration for systemic delivery of therapeutics |
| 10/14/2004 | WO2003087135A3 Novel pheromone receptor |